Biotech-Pharma (Therapy)

Compounds to induce satiation and control food intake, modulate body fat and regulate the lipid metabolism

A research group from the Andalusian Public Health System (SSPA) has identified a series of compounds to induce satiation, control food intake and modulate metabolic effects for their use in the treatment and/or prevention of metabolic and cardiovascular diseases.

Oficina de TRANSFERENCIA DE TECNOLOGÍA
Sistema Sanitario Público de Andalucía



Description

Cases of obesity and related diseases are increasing, which is a major problem for healthcare systems. Existing treatments are currently no more effective than dieting and there has been little success in developing drugs to induce a reduction of body weight in a sustained way with few side effects.

A research group from the Andalusian Public Health System has identified a series of compounds that exhibit an affinity for peroxisome proliferator-activated receptors (PPAR) and, therefore, modulate the actions regulated by them, such as inducing satiation, controlling food intake, and modulating metabolic effects. They consequently represent a new therapeutic alternative in the treatment and/or prevention of metabolic and cardiovascular diseases.

The technology developed by the group also includes the preparation procedure for the compound and its method of use.

Advantages

The proof of concept conducted through *in vivo* experiments showed that:

1. It successfully reduced food intake by 50%: it showed an effect 120 minutes after administration which disappeared after 240 minutes afterwards. This trait means that the compound tested is especially interesting for acute administration.
2. In addition to reducing food intake by some 50%, it has a sustained effect for 240 minutes following administration; it also continues to have an effect 24 hours afterwards. This makes the assay compound interesting for chronic administration.

Intellectual Property

This technology is protected by patent.

Aim

The research group is looking for a license or a collaboration agreement.

Classification

Area: Biotech-Pharma (Therapy)
Technology: Small molecules
Pathology: Metabolic diseases and Endocrinology

JUNTA DE ANDALUCIA
CONSEJERÍA DE IGUALDAD, SALUD Y POLÍTICAS SOCIALES

FIMABIS
FUNDACIÓN PUBLICA ANDALUZA PARA LA INVESTIGACIÓN DE MÁLAGA EN BIOMEDICINA Y SALUD

Avda. Jorge Luis Borges, 15. bloque 3, 3º 29010. Málaga. SPAIN
☎+34 951 440 260 🖷 +34 951 440 263 ☞isabel.guerrero@fimabis.org
www.fimabis.org